{"title":"Efficacy and tolerance of a prebiotic, panthenol-containing repair balm in patients diagnosed with skin lesions requiring regenerative care.","authors":"Stamatios Gregoriou, Efstratios Vakirlis, Efterpi Zafiriou","doi":"10.1684/ejd.2025.4855","DOIUrl":null,"url":null,"abstract":"<p><p>Skin lesions requiring regenerative care often present significant challenges for patient treatment and management. To assess the efficacy and tolerance of a soothing and repairing balm product (Cicaplast Baume B5+, La Roche-Posay, France) when used for the treatment of skin lesions requiring regenerative care, as well as its impact on quality of life (QoL) and patient satisfaction. Patients requiring regenerative care for superficial wounds or irritative dermatitis, or requiring sedative skin care after irritating treatments, such as for actinic keratosis (AK), or skin care following a dermatological procedure were included in the study. Initially, patients' QoL and clinical characteristics were assessed, and the product was then administered appropriately. During a second visit, all clinical and QoL parameters were re-evaluated, and product tolerance rate and satisfaction were assessed. In total, 2,337 subjects participated in the study. After the recommended period of use, a significant improvement in all clinical parameters examined was observed, with ≥64.9% of patients demonstrating an improvement of at least one grade for all assessed clinical symptoms, compared to the initial visit. A significant improvement in all skin discomfort parameters examined was also observed, with ≥81.2% of patients showing an improvement of at least one grade, along with a significant reduction in DLQI and CDLQI mean scores, by 67.7% and 69.8%, respectively (p<0.001), with a high tolerance rate and overall product satisfaction. This product showed significant improvement for all evaluated clinical parameters and patient QoL, with high tolerance and satisfaction rates.</p>","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"35 2","pages":"118-126"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/ejd.2025.4855","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Skin lesions requiring regenerative care often present significant challenges for patient treatment and management. To assess the efficacy and tolerance of a soothing and repairing balm product (Cicaplast Baume B5+, La Roche-Posay, France) when used for the treatment of skin lesions requiring regenerative care, as well as its impact on quality of life (QoL) and patient satisfaction. Patients requiring regenerative care for superficial wounds or irritative dermatitis, or requiring sedative skin care after irritating treatments, such as for actinic keratosis (AK), or skin care following a dermatological procedure were included in the study. Initially, patients' QoL and clinical characteristics were assessed, and the product was then administered appropriately. During a second visit, all clinical and QoL parameters were re-evaluated, and product tolerance rate and satisfaction were assessed. In total, 2,337 subjects participated in the study. After the recommended period of use, a significant improvement in all clinical parameters examined was observed, with ≥64.9% of patients demonstrating an improvement of at least one grade for all assessed clinical symptoms, compared to the initial visit. A significant improvement in all skin discomfort parameters examined was also observed, with ≥81.2% of patients showing an improvement of at least one grade, along with a significant reduction in DLQI and CDLQI mean scores, by 67.7% and 69.8%, respectively (p<0.001), with a high tolerance rate and overall product satisfaction. This product showed significant improvement for all evaluated clinical parameters and patient QoL, with high tolerance and satisfaction rates.
期刊介绍:
The European Journal of Dermatology is an internationally renowned journal for dermatologists and scientists involved in clinical dermatology and skin biology.
Original articles on clinical dermatology, skin biology, immunology and cell biology are published, along with review articles, which offer readers a broader view of the available literature. Each issue also has an important correspondence section, which contains brief clinical and investigative reports and letters concerning articles previously published in the EJD.
The policy of the EJD is to bring together a large network of specialists from all over the world through a series of editorial offices in France, Germany, Italy, Spain and the USA.